Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Neurology

Recognizing Symptoms and Subtypes

At a Glance

Hereditary ATTR amyloidosis can affect several body systems at once, especially the nerves and heart. The TTR gene variant may suggest a pattern, but symptoms vary, so unexplained nerve, heart, digestive, eye, or kidney problems warrant coordinated evaluation.

While the “h” in hATTR stands for hereditary, the “A” stands for amyloidosis, a condition that affects your entire body. It is a systemic disease, meaning it is not confined to just one organ like the heart or the nerves [1]. Because the unstable TTR protein travels through your bloodstream, it can deposit almost anywhere, leading to a wide range of symptoms that may at first seem unrelated [2].

Clinically Important Mutations

There are many known variants in the TTR gene, though not all are pathogenic (disease-causing). While your mutation provides a “guide” for what to expect, it is not a certain roadmap; the importance and phenotype of variants vary by geography, ancestry, and even among family members [3]. Medical records sometimes use updated scientific naming (like p.Val50Met) alongside historical names (like V30M).

  • V30M (p.Val50Met): This is the most common mutation globally [4]. It is often categorized by when symptoms start. Early-onset (usually in your 20s or 30s) often begins with autonomic dysfunction—issues with involuntary functions like digestion and blood pressure—and pain or temperature numbness in the feet [4][5]. Late-onset (after age 50) tends to involve all types of nerve fibers, causing weakness and loss of sensation [6].
  • V122I (p.Val142Ile): This mutation has a strong ancestry association, found in approximately 3% to 3.5% of larger studied populations of African descent [7]. It primarily causes cardiomyopathy—a thickening and stiffening of the heart walls—usually appearing after age 65 [8]. While often called a “cardiac” mutation, many patients also develop clinically important nerve damage, so both systems must be monitored [9].
  • T60A (p.Thr80Ala): Often referred to as a “mixed phenotype,” this mutation frequently causes both significant neurological disease and heart involvement, notably in US cohorts [10]. Research suggests that in some families, the nerve symptoms (neuropathy) may actually be more prominent and progress faster than the heart symptoms [11].

A Master of Disguise: Common Misdiagnoses

Because hATTR symptoms mimic more common conditions, many patients are misdiagnosed for years. Knowing these “mimics” can help you and your doctor ensure you are on the right treatment path.

  1. CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy): This is a recognized misdiagnosis [12]. CIDP is an autoimmune condition where the immune system attacks the nerve’s “insulation” (myelin). In hATTR, the nerve itself (the axon) is dying. When this axonal degeneration becomes severe, it can trick standard nerve tests into looking like demyelination [13]. Lack of response to standard CIDP treatment (IVIg) is sometimes a clue, but it is not diagnostic by itself, and you should never change immunotherapy without your clinician [2].
  2. Hypertrophic Cardiomyopathy (HCM): When hATTR affects the heart, the walls thicken, mimicking “typical” heart failure or HCM [1]. Clues that should prompt evaluation for ATTR include a thick heart wall alongside normal or low blood pressure, or having had carpal tunnel syndrome in both hands years before the heart issues started. These are nonspecific associations rather than definitive proof of hATTR, but they are important prompts for imaging and laboratory testing [14][1].
  3. Spinal Stenosis: Amyloid can also deposit in the ligaments of your spine, causing narrowing (stenosis) that leads to back pain and leg weakness [15]. If you have had back surgery but your “nerve pain” continues to get worse, it may be a sign of systemic amyloidosis [1].

Recognizing Multisystem Symptoms

Because hATTR is systemic, you may experience symptoms in several different “systems” at once:

  • Autonomic System: This controls your “automatic” functions. Damage here leads to orthostatic hypotension (a sharp drop in blood pressure when you stand up, causing dizziness), or sudomotor dysfunction (abnormal sweating) [16][17].
  • Gastrointestinal (GI): Amyloid in the gut can cause “early satiety” (feeling full after just a few bites), severe constipation alternating with “post-meal” diarrhea, and unexplained weight loss [16].
  • Ocular (Eyes): In some mutations, amyloid can form in the gel of the eye (the vitreous), appearing as “floaters,” or it can affect the blood vessels in the retina [3][18].
  • Renal (Kidneys): While less common than heart or nerve issues, some patients develop protein in their urine, a sign that amyloid is affecting kidney filtration [3].

Common questions in this guide

What symptoms can hereditary ATTR amyloidosis cause?
Hereditary ATTR amyloidosis can affect several body systems. Symptoms may include numbness or burning pain, weakness, dizziness when standing, abnormal sweating, digestive problems, thickened heart walls, eye floaters, or protein in the urine.
How do the V30M, V122I, and T60A mutations differ?
V30M often causes autonomic problems and nerve symptoms early in life, while later-onset V30M may cause more widespread nerve damage. V122I is often linked to heart muscle disease later in life, although nerve damage can also occur. T60A commonly has a mixed pattern involving both the nerves and heart, but symptoms vary among individuals and families.
Can hereditary ATTR amyloidosis be mistaken for CIDP?
Yes. Severe nerve-fiber damage from hereditary ATTR amyloidosis can sometimes make nerve tests look as if the nerve insulation is affected, resembling CIDP. A poor response to IVIg may raise questions, but it does not prove the diagnosis, and immunotherapy should not be changed without medical guidance.
What heart-related clues might suggest hereditary ATTR amyloidosis?
A thickened or stiff heart alongside normal or low blood pressure can prompt an evaluation for ATTR amyloidosis. Carpal tunnel syndrome in both hands, especially years before heart problems, can also be a clue. These findings are not diagnostic by themselves and require appropriate imaging and laboratory testing.
Does my TTR mutation predict exactly which symptoms I will develop?
No. A TTR variant can suggest whether nerve, heart, or mixed symptoms may be more likely, but disease patterns vary by geography, ancestry, and family member. Monitoring often needs to include both the heart and nerves, along with other systems based on your symptoms.
What non-nerve symptoms should someone with hereditary ATTR watch for?
Pay attention to dizziness after standing, unusual sweating, early fullness when eating, constipation alternating with diarrhea, unexplained weight loss, new eye floaters, or protein found in the urine. Report these changes to your care team because they may indicate involvement beyond the nerves.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my specific mutation, should we be monitoring my heart or my nerves more closely, or both equally?
  2. 2.If my nerve conduction studies show signs of demyelination, how can we be sure it is not actually axonal damage from hATTR mimicking CIDP?
  3. 3.What specific tests will you use to monitor my autonomic system for things like blood pressure changes or digestive issues?
  4. 4.Should I have a baseline eye exam to check for amyloid deposits in my vitreous or retina?
  5. 5.Does the presence of bilateral carpal tunnel syndrome or spinal stenosis in my history change how you view my current disease stage?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review.

    Ruberg FL, Grogan M, Hanna M, et al.

    Journal of the American College of Cardiology 2019; (73(22)):2872-2891 doi:10.1016/j.jacc.2019.04.003.

    PMID: 31171094
  2. 2

    Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy.

    Adams D, Ando Y, Beirão JM, et al.

    Journal of neurology 2021; (268(6)):2109-2122 doi:10.1007/s00415-019-09688-0.

    PMID: 31907599
  3. 3

    Optimal practices for the management of hereditary transthyretin amyloidosis: real-world experience from Japan, Brazil, and Portugal.

    Ando Y, Waddington-Cruz M, Sekijima Y, et al.

    Orphanet journal of rare diseases 2023; (18(1)):323 doi:10.1186/s13023-023-02910-3.

    PMID: 37828588
  4. 4

    Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update.

    Dispenzieri A, Coelho T, Conceição I, et al.

    Orphanet journal of rare diseases 2022; (17(1)):236 doi:10.1186/s13023-022-02359-w.

    PMID: 35717381
  5. 5

    Genetic and clinical features of hereditary transthyretin amyloidosis: a decade of experience at a Japanese referral center.

    Nomura T, Misumi Y, Tasaki M, et al.

    Orphanet journal of rare diseases 2025; (20(1)):474 doi:10.1186/s13023-025-04006-6.

    PMID: 40898332
  6. 6

    Drug and Gene Therapy for Treating Variant Transthyretin Amyloidosis (ATTRv) Neuropathy.

    Dardiotis E, Kyriakides T

    Current neuropharmacology 2023; (21(3)):471-481 doi:10.2174/1570159X21666221108094736.

    PMID: 36366846
  7. 7

    Prevalence and Outcomes of p.Val142Ile TTR Amyloidosis Cardiomyopathy: A Systematic Review.

    Chandrashekar P, Alhuneafat L, Mannello M, et al.

    Circulation. Genomic and precision medicine 2021; (14(5)):e003356 doi:10.1161/CIRCGEN.121.003356.

    PMID: 34461737
  8. 8

    Hereditary transthyretin amyloidosis caused by the Val142Ile variant in Spain.

    de Frutos F, Herrador L, Peiró-Aventín B, et al.

    Revista espanola de cardiologia (English ed.) 2025; (78(9)):768-777 doi:10.1016/j.rec.2024.12.012.

    PMID: 39827963
  9. 9

    Peripheral Nervous System Involvement of Hereditary Transthyretin Amyloidosis in the United States: A Multi-Center Perspective.

    Desai U, Ilieva HS, Eyer JE, Peltier AC

    Muscle & nerve 2025; (72(2)):286-293 doi:10.1002/mus.28414.

    PMID: 40395027
  10. 10

    Hereditary ATTR amyloidosis: a single-institution experience with 266 patients.

    Swiecicki PL, Zhen DB, Mauermann ML, et al.

    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2015; (22(2)):123-31 doi:10.3109/13506129.2015.1019610.

    PMID: 26017327
  11. 11

    Phenotypic Presentation and Longitudinal Characterization of Hereditary ATTRv Amyloidosis in Previously Undiagnosed Family Members.

    Fazzini L, Castrichini M, Li Y, et al.

    JACC. Advances 2025; (4(8)):102036 doi:10.1016/j.jacadv.2025.102036.

    PMID: 40712265
  12. 12

    Electrophysiological demyelinating features in hereditary ATTR amyloidosis.

    Ohashi N, Kodaira M, Morita H, Sekijima Y

    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2019; (26(1)):15-23 doi:10.1080/13506129.2018.1564903.

    PMID: 30688105
  13. 13

    Diagnosis of hereditary transthyretin amyloidosis in patients with suspected chronic inflammatory demyelinating polyneuropathy unresponsive to intravenous immunoglobulins: results of a retrospective study.

    Péréon Y, Adams D, Camdessanché JP, et al.

    Orphanet journal of rare diseases 2025; (20(1)):95 doi:10.1186/s13023-025-03589-4.

    PMID: 40025610
  14. 14

    Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis.

    Maurer MS, Bokhari S, Damy T, et al.

    Circulation. Heart failure 2019; (12(9)):e006075 doi:10.1161/CIRCHEARTFAILURE.119.006075.

    PMID: 31480867
  15. 15

    Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS).

    Damy T, Kristen AV, Suhr OB, et al.

    European heart journal 2022; (43(5)):391-400 doi:10.1093/eurheartj/ehz173.

    PMID: 30938420
  16. 16

    Role of ambulatory blood pressure monitoring as a non-invasive autonomic screening tool in hereditary transthyretin amyloidosis.

    Sander L, Chiaro G, Abelardo D, et al.

    Journal of neurology, neurosurgery, and psychiatry 2026; (97(3)):274-277 doi:10.1136/jnnp-2025-337061.

    PMID: 41390239
  17. 17

    Early cardiovascular autonomic failure in ATTRv predicts poor prognosis and may respond to disease-modifying therapy.

    Sander L, Chiaro G, Abelardo D, et al.

    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2025; (32(3)):246-254 doi:10.1080/13506129.2025.2494657.

    PMID: 40275642
  18. 18

    OPHTHALMOLOGIC INVOLVEMENT IN PATIENTS WITH HEREDITARY TRANSTHYRETIN AMYLOIDOSIS.

    Ruiz-Medrano J, Puertas M, Almazán-Alonso E, et al.

    Retina (Philadelphia, Pa.) 2023; (43(1)):49-56 doi:10.1097/IAE.0000000000003641.

    PMID: 36228151

This page is for informational purposes only and does not constitute medical advice. Your care team should interpret your TTR variant, symptoms, and test results and guide monitoring decisions.

Get notified when new evidence is published on Hereditary ATTR amyloidosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.